FR2781676B1 - Trimere du produit d'expression du gene env de hiv - Google Patents

Trimere du produit d'expression du gene env de hiv

Info

Publication number
FR2781676B1
FR2781676B1 FR9810027A FR9810027A FR2781676B1 FR 2781676 B1 FR2781676 B1 FR 2781676B1 FR 9810027 A FR9810027 A FR 9810027A FR 9810027 A FR9810027 A FR 9810027A FR 2781676 B1 FR2781676 B1 FR 2781676B1
Authority
FR
France
Prior art keywords
quarter
gene expression
expression product
env gene
hiv env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9810027A
Other languages
English (en)
Other versions
FR2781676A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Priority to FR9810027A priority Critical patent/FR2781676B1/fr
Priority to CA002338020A priority patent/CA2338020A1/fr
Priority to EP99934806A priority patent/EP1100926A1/fr
Priority to US09/744,659 priority patent/US6737067B1/en
Priority to PCT/FR1999/001871 priority patent/WO2000008167A1/fr
Priority to AU50459/99A priority patent/AU5045999A/en
Publication of FR2781676A1 publication Critical patent/FR2781676A1/fr
Application granted granted Critical
Publication of FR2781676B1 publication Critical patent/FR2781676B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9810027A 1998-07-31 1998-07-31 Trimere du produit d'expression du gene env de hiv Expired - Fee Related FR2781676B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9810027A FR2781676B1 (fr) 1998-07-31 1998-07-31 Trimere du produit d'expression du gene env de hiv
CA002338020A CA2338020A1 (fr) 1998-07-31 1999-07-29 Trimere du produit d'expression du gene env de hiv
EP99934806A EP1100926A1 (fr) 1998-07-31 1999-07-29 TRIMERE DU PRODUIT D'EXPRESSION DU GENE $i(ENV) DE HIV
US09/744,659 US6737067B1 (en) 1998-07-31 1999-07-29 Trimer of HIV env gene expression product
PCT/FR1999/001871 WO2000008167A1 (fr) 1998-07-31 1999-07-29 Trimere du produit d'expression du gene env de hiv
AU50459/99A AU5045999A (en) 1998-07-31 1999-07-29 Trimer of HIV (ENV) gene expression product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810027A FR2781676B1 (fr) 1998-07-31 1998-07-31 Trimere du produit d'expression du gene env de hiv

Publications (2)

Publication Number Publication Date
FR2781676A1 FR2781676A1 (fr) 2000-02-04
FR2781676B1 true FR2781676B1 (fr) 2004-04-02

Family

ID=9529397

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9810027A Expired - Fee Related FR2781676B1 (fr) 1998-07-31 1998-07-31 Trimere du produit d'expression du gene env de hiv

Country Status (6)

Country Link
US (1) US6737067B1 (fr)
EP (1) EP1100926A1 (fr)
AU (1) AU5045999A (fr)
CA (1) CA2338020A1 (fr)
FR (1) FR2781676B1 (fr)
WO (1) WO2000008167A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861253B2 (en) 2001-01-05 2005-03-01 Aventis Pasteur S.A. Polypeptide inducing antibodies neutralizing HIV
FR2830534B1 (fr) * 2001-10-05 2004-10-01 Aventis Pasteur Antigene polypeptidique formant une structure mimant l'etat intermediaire de gp41.
ES2275926T3 (es) * 2001-10-05 2007-06-16 Sanofi Pasteur Antigeno polipeptidico que forma una estructura que imita el estado intermedio de gp41.
US7056519B2 (en) 2002-05-17 2006-06-06 Aventis Pasteur S.A. Methods for inducing HIV-neutralizing antibodies
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
DK1831247T3 (da) * 2004-12-29 2009-10-12 Seattle Biomedical Res Inst Hetero-oligomere HIV-kappeproteiner
CA2655934A1 (fr) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Proteines env vih trimeriques solubles stabilisees et leurs utilisations
EP2040746A4 (fr) * 2006-06-19 2009-12-16 Progenics Pharm Inc Procedes de recuperation de formules stabilisees de trimeres de proteines d'enveloppe (env) retrovirale
WO2008063331A2 (fr) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US20150190501A1 (en) * 2011-09-12 2015-07-09 Imperial Innovations Limited Methods and compositions for raising an immune response to hiv
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122468A (en) * 1988-08-16 1992-06-16 Akzo N.V. Hut-78 cell lines infected with HTLV-III which secrete gp160
FR2692898B1 (fr) * 1992-06-30 1995-06-02 Centre Nat Rech Scient Procédé d'obtention de protéines membranaires, et utilisation de ces protéines dans un but de diagnostic ou de vaccination.
DE59402827D1 (de) * 1993-01-16 1997-06-26 Manfred Dr Schawaller Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
EP1019511A2 (fr) 1997-10-01 2000-07-19 Dana-Farber Cancer Institute Stabilisation des glycoproteines trimeres d'enveloppe au moyen de liaisons bisulfure introduites dans un ectodomaine de la glycoproteine gp41

Also Published As

Publication number Publication date
AU5045999A (en) 2000-02-28
CA2338020A1 (fr) 2000-02-17
US6737067B1 (en) 2004-05-18
WO2000008167A1 (fr) 2000-02-17
EP1100926A1 (fr) 2001-05-23
FR2781676A1 (fr) 2000-02-04

Similar Documents

Publication Publication Date Title
FR2781676B1 (fr) Trimere du produit d'expression du gene env de hiv
FR2832297B1 (fr) Ensemble de conditionnement et d'application d'un produit
FR2815832B1 (fr) Ensemble de conditionnement et d'application d'un produit, notamment cosmetique
DE69924930D1 (de) Synthese von Oligonukleotiden
FR2832598B1 (fr) Article de conditionnement et/ou d'application d'un produit
FR2800041B1 (fr) Ensemble de conditionnement et d'application d'un produit liquide
FR2833245B1 (fr) Ensemble applicateur d'un produit, notamment cosmetique
ID24757A (id) Pembuatan deterjen butiran
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
FR2771907B1 (fr) Ensemble de conditionnement et d'application d'un produit, notamment cosmetique
BR9609797A (pt) Inibição de expressão de gene
FR2789895B1 (fr) Produit cosmetique liquide
BR9609726A (pt) Inibição de expressão de gene
ID27831A (id) Aparatus penghasil suara
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
FR2760814B1 (fr) Produit tubulaire allonge, notamment du type conduit d'installation
AP2002002508A0 (en) The genome of the hiv-1 inter-subtype (d/b') and use thereof
FR2779925B1 (fr) Recipient distributeur d'un produit cosmetique en forme de baton
FR2746314B1 (fr) Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
FR2809313B1 (fr) Procedes de preparation de nouveaux supports a base de collagene pour l'ingenieurie tissulaire et biomateriaux obtenus
FI950389A (fi) Hemi-tuotteiden uusi lääkinnällinen käytt¦
FR2771737B1 (fr) Procedes de production et d'epuration de 1,1-difluoroethane et produit ainsi obtenu
FR2730476B1 (fr) Emballage-presentoir d'articles
FR2768448B1 (fr) Produit d'isolation phonique
FI973951A0 (fi) Boejlig skivformig produkt och foerfarande foer framstaellning daerav

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
RT Complete renunciation
ST Notification of lapse

Effective date: 20060331